MHRA Post-Brexit: 3 Key Challenges for Pharma in 2026
MHRA Post-Brexit: 3 Key Challenges for Pharma in 2026
The UK’s post-Brexit regulatory landscape is no longer a future concept—it’s a present-day reality. As we approach 2026, the full implications of the UK’s standalone regulatory framework are becoming clearer, and companies must be prepared.
The separation from the EMA has introduced new pathways, but also new complexities. This article highlights three key challenges that pharma and biotech companies need to have on their strategic radar for 2026.
1. The Windsor Framework & UK-Wide Licensing
Perhaps the most significant challenge is the full implementation of the Windsor Framework. From 1 January 2025, all new medicines for the UK market must be authorised by the MHRA.
The Challenge for 2026: Companies must have fully transitioned their supply chains and packaging. There will be no room for error in managing a single, UK-wide pack and supply chain, separate from any EU-specific (NI) arrangements that existed previously. This requires meticulous planning, especially for products with complex manufacturing.
2. Navigating UK-EU Regulatory Divergence
While the MHRA has adopted many EU guidelines, divergence is not just a risk—it’s a reality. The UK is actively carving its own path with pathways like ILAP and a different approach to data and AI.
The Challenge for 2026: Sponsors can no longer assume that a single EU-focused data package is sufficient. By 2026, you will need a clear strategy to manage two separate (though similar) regulatory systems. This could mean running additional UK-specific studies, preparing separate dossier sections, or managing different post-approval commitments, adding cost and complexity.
3. UK-Specific Data & Pharmacovigilance Systems
With the UK outside the EU’s data-sharing systems, companies are now fully responsible for operating separate UK-specific databases and safety systems.
The Challenge for 2026: The MHRA has high expectations for pharmacovigilance (PV). By 2026, your company must be running a robust, fully independent UK PV system, including a UK QPPV. This requires dedicated resources and expertise, a significant burden for small and medium-sized companies that previously relied on a single, pan-EU system.
How to Prepare Your 2026 Strategy
Navigating this new landscape requires a proactive, UK-specific strategy.
- Audit Your Portfolio: Review all your current and planned products. Which ones are most affected by the Windsor Framework?
- Embrace UK Pathways: Don’t just treat the UK as an afterthought. Actively explore the MHRA’s unique pathways, like ILAP, which can offer significant benefits.
- Resource for Divergence: Allocate budget and resources for managing two separate regulatory systems. This is the new cost of doing business.